Advertisement

Topics

Pfizer Inc. & Bristol-Myers Squibb Company Profile

17:03 EDT 19th March 2019 | BioPortfolio

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizer’s global scale and expertise in this field.


News Articles [1949 Associated News Articles listed on BioPortfolio]

Bristol-Myers and Squibb-Pfizer report positive AUGUSTUS trial data

The Bristol-Myers Squibb-Pfizer Alliance has reported positive results from the Phase IV AUGUSTUS trial that evaluated Eliquis (apixaban) versus vitamin...Read More... The post Bristol-Myers and Squib...

Bristol-Myers Squibb Awards “Golden Tickets” to ReviveMed and Strand Therapeutics

Bristol-Myers Squibb and LabCentral, a Cambridge, Mass.-based shared laboratory space, announced the two winners of the Bristol-Myers Squibb’s 2018 Golden Tickets for LabCentral. Due to being a plat...

Megafusion - Bristol-Myers Squibb will Celgene kaufen

Das ist ein verspäteter Silversterknaller. Bristol-Myers Squibb bietet 74 Milliarden USD für die Biotechfirma Celgene! Mit diesem Schritt könnte Bristol-Myers Squibb der führende Biopharma-Medikam...

Bristol-Myers Squibb Pulls 3 Programs out of CytomX Partnership

Bristol-Myers Squibb and South San Francisco-based CytomX Therapeutics have been collaborating since 2014, a deal that was boosted in 2017 when Bristol-Myers Squibb added up to eight additional target...

Bristol-Myers and Pfizer report positive AUGUSTUS trial data

The Bristol-Myers Squibb-Pfizer Alliance has reported positive results from the Phase IV AUGUSTUS trial that evaluated Eliquis (apixaban) versus vitamin...Read More... The post Bristol-Myers and Pfize...

Deep Dive: Bristol-Myers Squibb's Celgene Acquisition

Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. ...

Starboard Value Opposes Bristol-Myers Squibb's Acquisition Of Celgene

SUMMIT (dpa-AFX) - Starboard Value LP, a stockholder of Bristol-Myers Squibb Company (BMY), said that it has delivered an open letter to Bristol-Myers stockholders expressing its belief that the p...

Bristol-Myers Squibb Strikes Back! Response to Critics of Celgene Deal

Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholde...

Drugs and Medications [121 Associated Drugs and Medications listed on BioPortfolio]

Entecavir [accord healthcare inc.]

These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets, for oral use Ini...

Entecavir [golden state medical supply inc.]

ENTECAVIR TABLETS These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS . ENTECAVIR tablets...

Vyndaqel [pfizer labs division of pfizer inc.]

Vyndaqel

Entecavir [avkare, inc.]

Entecavir Tablets These highlights do not include all the information needed to use ENTECAVIR TABLETS safely and effectively. See full prescribing information for ENTECAVIR TABLETS. ENTECAVIR tablets,...

Entecavir [par pharmaceutical, inc.]

These highlights do not include all the information needed to use Entecavir Tablets safely and effectively. See full prescribing information for Entecavir Tablets.Entecavir tablets, for oral useInitia...

PubMed Articles [123 Associated PubMed Articles listed on BioPortfolio]

A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients.

Belatacept (Nulojix; Bristol-Myers Squibb, New York, NY) is a biological immunosuppressive drug used for the prophylaxis of acute rejection after renal transplantation. Few studies have described bela...

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.

The unprecedented success of immuno-oncology (I-O) agents targeting the cytotoxic T lymphocyte-associated antigen 4 and programmed death-1/programmed death-ligand 1 pathways has stimulated the rapid...

Nivolumab for Treating Metastatic or Unresectable Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (Bristol-Myers Squibb) of nivolumab (Opdivo) to submit e...

A qualitative evaluation of the appropriateness, validity, acceptability, feasibility and interpretability of the Bristol Impact of Hypermobility (BIoH) questionnaire.

The Bristol Impact of Hypermobility (BIoH) questionnaire is a condition-specific patient-reported outcome measure developed for adults with Joint Hypermobility Syndrome (JHS). It has previously demons...

Copper Toxicity in Bristol Bay Headwaters: Part 1-Acute Mortality and Ambient Water Quality Criteria in Low-Hardness Water.

The world-class Bristol Bay (Alaska) salmon fishery and vast deposits of copper and other metals in the watershed warrant further investigation into the potential toxicity of copper to salmonids under...

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Prodactariv 60 mg F.C.T (International Drug Agency for Pha...

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Daclatasvir from Daktavira 60 mg film coated tablets ( European Egyptian Ph...

Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Glucophage®, Bristol-Myers Squibb Company) in Fed, Healthy, Adult Subjects

- Objective: - A Randomized, Two-Way Crossover, Single-Dose, Open-Label Study to Evaluate the Bioequivalence of a Test Tablet Formulation of Metformin HCl (1000 mg), Co...

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Companies [227 Associated Companies listed on BioPortfolio]

Bristol-Myers Squibb Company & Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize ELIQUIS, an investigational oral anticoagulant discovered by Bristol-M...

Pfizer Inc. & Bristol-Myers Squibb

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb and Pfizer

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

Bristol-Myers Squibb Company and Pfizer Inc.

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize Eliquis, an oral anticoagulant discovered by Bristol-Myers Squibb. Thi...

Bristol-Myers Squibb-Pfizer Alliance

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. Th...

More Information about "Pfizer Inc. & Bristol-Myers Squibb" on BioPortfolio

We have published hundreds of Pfizer Inc. & Bristol-Myers Squibb news stories on BioPortfolio along with dozens of Pfizer Inc. & Bristol-Myers Squibb Clinical Trials and PubMed Articles about Pfizer Inc. & Bristol-Myers Squibb for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pfizer Inc. & Bristol-Myers Squibb Companies in our database. You can also find out about relevant Pfizer Inc. & Bristol-Myers Squibb Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record